A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
← catalyst calendarNCT07255404 · readout ≤ 499 d
Sponsored by BioNTech SE (industry) · BNTX — their whole pipeline →. With Bristol-Myers Squibb, BioNTech (Shanghai) Pharmaceuticals Co., Ltd..
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
105estimated
Sites
24
Countries
Australia, China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-04 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
- Drug: Pumitamig — also filed as BNT327, PM8002, BMS-986545
- Drug: Nab-paclitaxel
- Drug: Gemcitabine
- Drug: mFOLFIRINOX
Primary outcomes
what the primary-completion date above is the date OFConfirmed overall response rate
measured Up to 24 months
Occurrence of treatment emergent adverse events (TEAEs) by severity
measured From the first dose of study treatment until 90 days after the last dose of study treatment (up to 32 months).
Occurrence of dose interruptions, reductions, and discontinuations due to TEAEs
measured Up to 24 months after first dose
Permalink · BNTX's whole pipeline · Catalyst calendar · Every registered study · What changed